Altimmune (NASDAQ:ALT) Now Covered by Truist Financial

Truist Financial began coverage on shares of Altimmune (NASDAQ:ALT) in a report issued on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $12.00 price objective on the stock.

A number of other research analysts have also weighed in on ALT. B. Riley Financial dropped their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Thursday, March 5th. HC Wainwright raised their price target on shares of Altimmune from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Finally, Wall Street Zen lowered Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Altimmune has an average rating of “Moderate Buy” and an average price target of $18.00.

Altimmune Trading Down 3.1%

NASDAQ ALT opened at $3.42 on Wednesday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.15. Altimmune has a 52 week low of $2.90 and a 52 week high of $7.73. The business has a 50 day moving average price of $4.46 and a 200-day moving average price of $4.29. The company has a market cap of $444.84 million, a price-to-earnings ratio of -3.39 and a beta of 0.13.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, equities analysts expect that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Altimmune

In other news, Director John Gill purchased 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were acquired at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the acquisition, the director owned 12,500 shares in the company, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jerome Benedict Durso acquired 20,000 shares of Altimmune stock in a transaction on Friday, March 6th. The stock was purchased at an average cost of $3.54 per share, with a total value of $70,800.00. Following the completion of the transaction, the chief executive officer directly owned 32,500 shares in the company, valued at $115,050. This represents a 160.00% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 55,527 shares of company stock valued at $213,778. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Arax Advisory Partners increased its position in shares of Altimmune by 99.7% during the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after acquiring an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after purchasing an additional 1,928 shares during the last quarter. Quadrature Capital Ltd purchased a new position in Altimmune in the fourth quarter worth $36,000. Victory Capital Management Inc. bought a new position in Altimmune in the 3rd quarter valued at $38,000. Finally, CreativeOne Wealth LLC bought a new position in Altimmune in the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Key Headlines Impacting Altimmune

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Truist initiated coverage with a “Buy” and a $12.00 price target (roughly 250% upside vs. current levels), which could attract buyers and improve sentiment. Read More.
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $25 price target and raised several near‑term EPS forecasts (Q1–Q4 2026 and FY2026/FY2027 upgrades and smaller quarter‑by‑quarter EPS improvements), signaling improved near‑term operating expectations. Read More.
• Neutral Sentiment: Reported short‑interest entries show a large “increase” but list 0 shares and NaN changes, with days‑to‑cover = 0.0 — this appears to be a data glitch and unlikely to have a clear market effect unless corrected. (No external link available)
• Negative Sentiment: HC Wainwright also trimmed longer‑term forecasts materially (FY2028 and FY2029 EPS were reduced), indicating weaker expected longer‑term profitability; this could limit enthusiasm for the very high $25 PT or lead some investors to remain cautious. Read More.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.